Autres langues Evofem Biosciences, Inc.

Actions

EVFM

US30048L3024

Produits pharmaceutiques

Marché Fermé - OTC Markets 21:59:24 04/06/2026			Varia. 5j.	Varia. 1 janv.
0,008500 ^USD	+7,59%		+13,33%	-10,53%

14/08	Evofem Biosciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
01/07	HUB Cyber Security acquiert des obligations convertibles d'Evofem et réduit ses effectifs	MT

Autres langues

14/08	Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
23/07	Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
01/07	HUB Cyber Security Acquires Evofem Notes, Cuts Staff
18/05	Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
15/05	Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/04	Evofem Biosciences, Inc. and Clovis Davis Pharmaceuticals, LLC Enter Exclusive Distribution Agreement For SOLOSEC In Sub-Saharan Africa
27/04	Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
19/03	Evofem Biosciences, Inc. Announces Termination of License and Supply Agreement with No Fees Payable with Windtree Therapeutics, Inc
11/03	Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
11/03	Evofem Reports Fifth Consecutive Year of Net Sales Growth
11/03	Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
21/11	Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
13/11	Evofem Biosciences Q3 net sales rise
13/11	Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
13/11	Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
11/11	Evofem Biosciences : EVFM Investor Presentation Nov 2025
20/10/25	Aditxt, Inc. cancelled the acquisition of Evofem Biosciences, Inc. from Keystone Capital Partners LLC and others.
01/10/25	Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
01/10/25	Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
12/09/25	EVFM Investor Presentation: 12 September 2025
09/09/25	Evofem Biosciences : Special Meeting of Stockholders
09/09/25	Evofem anticipates approval of merger with Aditxt at upcoming Stockholder Meeting
05/09/25	Evofem Biosciences : EVFM Corporate Update 5 September 2025
19/08/25	FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
14/08/25	Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025